CRN Meeting 2026 Website

**Professor Greg Dore** is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care, and public health policy for 25 years. He has developed extensive national and international collaborations and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

Professor Dore established the St Vincent’s Hospital viral hepatitis service in 1999 and has led its development into one of the leading national and international HCV treatment services, with a particular focus on marginalised populations including people who inject drugs and homeless persons.

**Professor Greg Fox** is the Director of the Sydney Southeast Asia Centre at the University of Sydney, and Professor of Respiratory Medicine. He has led clinical trials and research relating to infectious diseases and chronic diseases for the University of Sydney in Vietnam for over a decade. His research group in Vietnam has conducted multi-centre studies into the prevention and detection of tuberculosis and other lung diseases in resource-limited settings. His research, in combination with guideline development work for the World Health Organisation, have contributed to changes in global TB policies and clinical practice.

Professor Fox works clinically as a Respiratory Physician at Sydney’s Royal Prince Alfred Hospital, is Area Director for Tuberculosis Services for Sydney Local Health District. He is also strongly committed to building research capacity in Australia and internationally.

**Professor David Paterson** directs ADVANCE-ID (ADVANcing Clinical Evidence for Infectious Diseases) at Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine at National University of Singapore. ADVANCE-ID is a clinical trials network comprising more than 100 hospitals across 20 countries in Asia. This network is jointly funded by the Wellcome Trust and a number of Singaporean institutions with an aim to conduct clinically important trials in the field of antimicrobial resistance (AMR). This comprises trials of antibiotics, diagnostics and prevention strategies. He is also an Honorary Professor at the University of Queensland and has more than 600 peer-reviewed publications predominantly in the area of AMR. His research focuses on the molecular and clinical epidemiology of infections with antibiotic-resistant organisms, with the intent of translating knowledge into optimal prevention and treatment of these infections. Multi-country clinical trials are the major component of his research portfolio, and the predominant focus of ADVANCE-ID.

**Prof Jane Davies** is a Senior Principal Research Fellow at the Menzies School of Health Research and Co-Director of Infectious Diseases at Royal Darwin Hospital. Her research focuses on understanding and optimising care for infections with a focus on Aboriginal and Torres Strait Islander people in the Northern Territory of Australia. She leads the Hepatitis B PAST program, a holistic model of care co-designed to deliver care on country for viral hepatitis and liver cancer screening. Prof Davies works clinically as an Infectious Diseases and General Medicine Physician at the Royal Darwin Hospital and leads the clinical Viral Hepatitis Service.

**Dr Karen Wright** (Kāi Tahu) is a public health physician and senior lecturer at Te Kupenga Hauora Māori, Waipapa Taumata Rau | University of Auckland. Karen’s research is centred around the transformation of health systems, services, and programmes to uphold Indigenous rights and achieve equitable outcomes. Research topics are broad but include COVID-19 risk prediction, acute rheumatic fever, and anti-microbial stewardship.

**Dr Sophie Wen** is a Paediatric Infectious Diseases specialist at Queensland Children's Hospital whose research focuses on patient-centred outcomes for children with serious infections. Her work spans qualitative research, patient-reported outcome measures (PROMs), and clinical trial methodology to ensure that the perspectives of children and families shape the design of future paediatric research.

**Dr David Goodman-Meza**, MD, PhD, is a physician-scientist with expertise in Infectious Diseases and Addiction Medicine. He is currently a Senior Research Associate at Kirby Institute at the University of New South Wales and a Staff Specialist at St Vincent’s Hospital and Parklea Correctional Centre. He received his MD with honors from Universidad Autonoma de Baja California in Tijuana, Mexico and a master's in clinical research at UCSD, and PhD at UNSW. His research work is focused on the relationship of substance use disorders and infectious diseases using data science and developing interventions to improve health outcomes in this vulnerable population.

**Professor Jason Roberts** is Deputy Director of the Frazer Institute at the University of Queensland and is Interim Director of the Herston Infectious Diseases Institute (HeIDI). Academically he is an Australian National Health and Medical Research Council Leadership Fellow and a Fellow of the Australian Academy for Health and Medical Sciences. Clinically, he is a critical care pharmacist at Royal Brisbane and Women’s Hospital.

**Dr Aidan Cashin** (PhD, BExPhys) is a NHMRC Emerging Leadership Fellow and UNSW Scientia Fellow in the School of Population Health at UNSW. He is forging a career as a clinical pain scientist with a focus on applying causal inference methods to drive evidence translation from clinical trials and observational studies to practice and policy. His research program is accommodated within the Centre for Pain IMPACT (Investigating Mechanisms of Pain to Advance Clinical Translation), which he is the Deputy Director. His research is supported by over $17 million in competitive national and international research funding and is focused on developing, testing, and optimising healthcare interventions to improve chronic pain management.

**Professor Trisha Peel** is a L1 NHMRC Fellow and a recognised leader in infectious diseases research. Based at Monash University and Alfred Health, she is appointed as Deputy Director in the Department of Infectious Diseases. Her work focuses on preventing and managing infections in patients undergoing surgery, leading large studies that have improved outcomes for patients. She collaborates with a broad range of experts, including surgeons, anaesthetists, and consumers, to ensure her research addresses real-world needs. Her findings have been published in top journals, such as the New England Journal of Medicine, and she has received multiple awards, including the 2024 ACTA Trial of the Year, for her contributions to better patient care.

**Dr Rekha Pai Mangalore** is an Infectious Diseases and General Physician, Alfred Hospital, Bayside Health, Melbourne. She is a clinician-researcher, adjunct lecturer at Monash University. Her interests include translational research and provision of precise, individualised patient care with a focus on precision dosing and real-time monitoring of antimicrobials. Her PhD was on beta-lactam antibiotic TDM led to successful implementation of a beta-lactam TDM service at Alfred Hospital. Dr Mangalore is a Board member and treasurer at ASID and the AMR Therapeutic Solutions Theme Leader at Centre to Impact AMR, Monash University.

Associate Professor Amanda Gwee MBBS FRACP DTMH PhD is the Leader of the Antimicrobials Group at Murdoch Children's Research Institute. She is a general paediatrician, infectious diseases physician, clinical pharmacologist, and Clinical Lead of Research in the Department of General Medicine at The Royal Children’s Hospital Melbourne. In addition, she is an Associate Professor in the Department of Paediatrics, at the University of Melbourne. Amanda's research program focuses on optimising antimicrobial use and access in children and includes early and late phase clinical trials, pharmacokinetic/pharmacodynamic studies, and cohort studies. She is passionate about improving medication use in children and is involved in several international guideline/expert groups (European Society for Paediatric Infectious Diseases, WHO, Therapeutic Guidelines).

**A/Prof Phoebe Williams** is a Paediatrician and Infectious Diseases physician working as a Staff Specialist at Sydney Children’s Hospital, and a NHMRC Emerging Leadership Fellow at the University of Sydney. Her research focuses on antimicrobial resistance in neonates and children as the coordinating principal investigator of the neonatal sepsis in Southeast Asia and the Pacific consortium (www.neoseap.com). She works in the policy support team for the National Centre for Immunisation Research and Surveillance (NCIRS) and serves on the Global Research Agenda for AMR and Paediatric Drug Optimisation Committees for the World Health Organization (WHO).

Scientia Professor Rebecca Guy is a Public Health Epidemiologist and Head of the Surveillance and Evaluation Research Program at the Kirby Institute, UNSW. Her research focuses on reducing the impact of infectious diseases in vulnerable populations, including evaluating the effectiveness, acceptability, and cost-effectiveness of novel strategies, including point-of-care testing.